Allopurinol
Allopurinol is a pharmaceutical drug with 134 clinical trials. Currently 9 active trials ongoing. Historical success rate of 88.2%.
Success Metrics
Based on 97 completed trials
Phase Distribution
Phase Distribution
19
Early Stage
45
Mid Stage
54
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
84.3%
97 of 115 finished
15.7%
18 ended early
9
trials recruiting
134
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
A Study of Dotinurad Versus Allopurinol in Participants With Gout
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Uric Acid, Klotho and Salt Sensitivity in Young Adults Born Preterm
Clinical Trials (134)
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
A Study of Dotinurad Versus Allopurinol in Participants With Gout
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Uric Acid, Klotho and Salt Sensitivity in Young Adults Born Preterm
Evaluation of a Treatment With Allopurinol in Adenylosuccinate Lyase Deficiency
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
Allopurinol Improves Heart Function in African Americans With Resistant Hypertension
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
ALLOPURINOL AND LISINOPRIL FOR DIABETIC KIDNEY PROTECTION: A COMPARATIVE STUDY IN NORMOURICEMIC TYPE 2 DIABETICS
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
Extension Study of ABP-671 in Participants With Gout
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
Effect of Allopurinol on Markers of Mineral and Bone Metabolism
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 134